MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%
Sector Heatmap
Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%
OTLK — Outlook Therapeutics, Inc. Common Stock
NasdaqOutlook Therapeutics, Inc. Common Stock
$0.59
+0.02(+3.15%)
- O
- 0.60
- H
- 0.61
- L
- 0.58
- V
- 4.22M
⏱️ End-of-day dataAs of Oct 7, 2026
Chart
About OTLK
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateMay 13, 2016
Employees17
Stock ExchangeNasdaq
Ticker SymbolOTLK
Key Financial Statistics
| Market Cap | $144.36M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.16 - $2.54 |
| 52-Week Avg Volume | 10.35M |
| VWAP | $0.59 |
| Transactions | 5,390 |
| Total Recorded Bars | 2,594 days |